Therabene Inc. Announces Positive Preclinical Results for Two Promising New Molecules in Collaboration with Biocytogen
NORWOOD, MA / ACCESSWIRE / November 21, 2024 / Therabene Inc., an emerging biotech company at the forefront of developing advanced cancer therapies, is pleased to announce positive preclinical results for two new novel molecules targeting aggressive cancers. Conducted in collaboration with local biotech service provider Biocytogen, the study results highlight the efficacy of Therabene's innovative approach to cancer treatment, with both new molecules demonstrating compelling tumor reduction in the triple negative breast cancer model.
This breakthrough reinforces Therabene's commitment to pioneering life-changing therapies for cancers with limited treatment options, not only for triple-negative breast cancer, but also for lung cancer and pancreatic cancer. The recent preclinical study is an important milestone as Therabene progresses toward clinical trials.
"We are immensely encouraged by these preclinical results," said Dr. Mario DiPaola, CEO and founder of Therabene. "This very encouraging data validates our approach and motivates us to advance these molecules with the urgency that patients deserve. We are also proud of our partnership with Biocytogen, whose expertise was instrumental to achieving these results."
Lindy Yan, COO of Therabene, echoed this sentiment: "This successful collaboration with Biocytogen has been a powerful example of local biotech synergy. Their dedicated support enabled us to accelerate our preclinical efforts and reach this critical milestone. We're excited to continue our work together as we strive to develop impactful cancer therapies."
Therabene is committed to translating these preclinical findings into new clinical solutions that address the critical unmet medical needs of hard-to-treat cancer patients. With further research and partnership opportunities on the horizon, Therabene aims to maintain its momentum and bring these molecules closer to clinical testing.
For more information on Therabene and its research pipeline, visit www.therabene.com
About Therabene Inc.
Therabene Inc. is a biotech start-up company focused on creating first-in-class therapies for hard-to-treat cancers such as triple-negative breast cancer, lung cancer, and pancreatic cancer. Through a blend of innovative research and patient-centered values, Therabene strives to offer new treatment avenues for patients with limited options.
Media Contact
Lindy Yan
COO
Therabene Inc.
lyan@therabene.com
5082442904
SOURCE: Therabene Inc.
View the original press release on accesswire.com
